Drug Trial Radar · NCT02159066
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Last checked: Nov 20, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Jul 23, 2014
Primary completion
Jan 10, 2023
Study completion Jan 10, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.
Conditions
- Melanoma
Interventions
LGX818Drug
Combination of LGX818 and MEK162 (Part I)
MEK162Drug
Combination of LGX818 and MEK162 (Part I)
LEE011Drug
Combination of LGX818 + MEK162 + LEE011 (Part II)
BGJ398Drug
Combination of LGX818 + MEK162 + BGJ398 (Part II)
BKM120Drug
Combination of LGX818 + MEK162 + BKM120 (Part II)
INC280Drug
Combination of LGX818 + MEK162 + INC280 (Part II)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR): Part IITime frame: From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (maximum treatment exposure for Part II was 97.0 weeks)
Locations
32 sites in 9 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Cancer Care Center
Los Angeles, California
Doris Stein Research Center Building
Los Angeles, California
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
Los Angeles, California
UCLA Dermatology Clinic
Los Angeles, California
UCLA Oncology Center
Los Angeles, California
UCLA Radiology
Los Angeles, California
Memorial Sloan Kettering Cancer Center Attn: Geny O'neill
New York, New York
Memorial Sloan Kettering Cancer Center Inpatient Hospital & Main Campus
New York, New York
Memorial Sloan Kettering Cancer Center- Outpatient Clinic
New York, New York
OHSU Knight Cancer Institute
Portland, Oregon
OHSU Center for Health and Healing 2
Portland, Oregon
OHSU Center for Health and Healing
Portland, Oregon
OHSU Research Pharmacy Services
Portland, Oregon
Oregon Health and Science University
Portland, Oregon
Sarah Cannon Research Institute
Nashville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
East St Kilda Eye Clinic
Melbourne, Victoria, Australia
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Sir Mortimer B. Davis-Jewish General Hospital
Monteral, Quebec, Canada
Uniklinik Köln
Cologne, Germany
Städtisches Klinikum München
München, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
University Clinic Heidelberg PPDS
Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany
U.O.C. Oncologia Medica e Terapie Innovative Dipartimento di Melanoma IRCCS Fondazione G. Pascale
Naples, Italy
Azienda Ospedaliera Monaldi
Naples, Campania, Italy
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Hospital Universitario Vall d'Hebrón - PPDS
Barcelona Cataluna, Barcelona, Spain
Universitätsspital Zürich
Zurich Flughafen, Switzerland
Churchill Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.